Page 49 - CPG endometrial cancer

แนวทางการดูแลทางดา้ นสูตินรีเวชในผปู้ ว่ ยท่มี ีความผิดปกติทางพนั ธุกรรม BRCA
for cancer prevention and screening. Ann Oncol
2016;27 (suppl 5):v103-10.
7. Rebbeck TR, Kauff ND, Domchek SM. Meta-
analysis of risk reduction estimates associated
with risk-reducing salpingo-oophorectomy in
BRCA1 or BRCA2 mutation carriers. J Natl
Cancer Inst 2009;101:80-7.
8. Kauff ND, Domchek SM, Friebel TM, Robson
ME, Lee J, Garber JE, et al. Risk- reducing
salpingo-oophorectomy for the prevention of
BRCA1- and BRCA2- associated breast and
gynecologic cancer: a multicenter, prospective
study. J Clin Oncol 2008;26:1331-7.
9. Finch AP, Lubinski J, Moller P, Singer CF,
Karlan B, Senter L, et al. Impact of oophorectomy
on cancer incidence and mortality in women
with a BRCA1 or BRCA2 mutation. J Clin Oncol
2015;32:1547-53.
10. Powell CB, Chen LM, McLennan J, Crawfor B,
Zaloudek C, Rabban JT, et al. Risk- reducing
salpingo-oophorectomy (RRSO) in BRCA mutation
carriers: experience with a consecutive series of
111 patients using a standardized surgical-
pathological protocol. Int J Gynecol Cancer
2011;21:846-51.
40
11. Kauff ND, Satagopan JM, Robson ME,
Scheuer L, Hensley M, Hudis CA, et al. Risk-
reducing salpingo- oophorectomy in women
with a BRCA1 or BRCA2 mutation. N Engl J
Med 2002;346:1609-15.
12. สมาคมมะเร็งนรีเวชไทยและราชวิทยาลัยสูตินรี
แพทย์แห่งประเทศไทย. แนวทางการดูแลผู้ป่วย
มะเรง็ รงั ไข่. พี.ซ.ี เค.ดีไซน:์ นนทบุรี 2562.
13. Moore K, Colombo N, Scambia G, Kim BG,
Oaknin A, Friedlander M, et al. Maintenance
olaparib in patients with newly diagnosed
advanced ovarian cancer. N Engl J Med 2018;
379:2495-505.
14. Banerjee S, Moore K, Colombo N, Scambia G,
Kim BG, Oaknin A, et al. Maintenance olaparib
for patients with newly diagnosed advanced
ovarian cancer and a BRCAmutation(SOLO-1/
GOG3004): 5-year follow-up of a randomized,
double- blind, placebo- controlled, phase 3
trial. Lancet Oncol 2021;22:1721-31.
15. Pujade- Loraine E, Lederman JA, Selle F,
Gebski V, Penson RT, et al. Olaparib tablets
as maintenance therapy in patients with
platinum-sensitive, relapsed ovarian cancer